I-SPY2 PUBLICATIONS & ABSTRACTS
Clinical evidence from I-SPY2
Evidence / Neoadjuvant / I-SPY2
Neoadjuvant CT & Immunotherapy in HR+/HER2-negative breast cancer
Journal of Clinical Oncology, April 9, 2024 Presenter: Rios-Hoyo et al.
Read MoreI-SPY2: ImPrint immune signature identifies ESBC patients who benefit from PD1 checkpoint inhibition
ASCO 2022, Poster #514 Authors: Kuilman et al.
Read MoreDurvalumab + olaparib + paclitaxel in High-risk HER2-negative ESBC: I-SPY2 trial results
I-SPY2 Trial, Cancer Cell 39, 989–998, 2021 Authors: Pusztai et al.
Read MoreI-SPY2: Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer
I-SPY2, JAMA Oncology, 2020 Authors: Yee et al.
Read MoreBluePrint Luminal subtype predicts non-response to HER2-targeted therapies- I-SPY2
AACR, Poster 2612 AUTHORS: Pei Rong Evelyn Lee, Zelos Zhu, Denise Wolf, Christina Yau, William Audeh, Annuska Glas, Lamorna Brown-Swigart, Gillian Hirst, Angela DeMichele, ISPY2 TRIAL Investigators, Laura Esserman and Laura van ‘t Veer DESCRIPTION: BluePrint Luminal subtype predicts non-response to HER2-targeted therapies in HR+/HER2+ I-SPY2 breast cancer patients BluePrint® Read More
DNA Repair Deficiency Biomarkers and the 70-Gene Ultra-High Risk Signature as Predictors of Veliparib/Carboplatin Response in the I-SPY 2 Breast Cancer Trial
PUBLICATION: NPJ Breast Cancer. 2017 Aug 25;3:31. doi: 10.1038/s41523-017-0025-7. AUTHORS: Wolf D.M., Yau C., Sanil A., Glas A., Petricoin E., Wulfkuhle J., Severson T.M., Linn S., Brown-Swigart L., Hirst G., Buxton M., DeMichele A., Hylton N., Symmans F., Yee D., Paoloni M., Esserman L., Berry D., Rugo H., Olopade O., Read More
